Status:
COMPLETED
Celecoxib in Colposcopic Directed Biopsy
Lead Sponsor:
Cairo University
Conditions:
Colposcopy
Eligibility:
FEMALE
18-65 years
Phase:
PHASE4
Brief Summary
Women often experience pain and discomfort during colposcopic examination especially at time of colposcopic directed excisional biopsy, pre-procedure anxiety, women pain threshold may also increase pa...
Eligibility Criteria
Inclusion
- • Females 18-65 years old who undergoing colposcopic directed biopsy
Exclusion
- A known allergy to Celecoxib, aspirin or another NSAID.
- Active peptic ulceration or gastrointestinal bleeding.
- Inflammatory bowel disease.
- Congestive heart failure (NYHA II-IV).
- Established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
- History of neurologic deficit.
- Known hepatic or renal impairment.
- Pregnancy.
- Breast-feeding.
- Post-hysterectomy.
- Bleeding disorders.
- Drug abuse.
- Cervical and vaginal infection.
Key Trial Info
Start Date :
April 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT03464552
Start Date
April 15 2018
End Date
June 30 2019
Last Update
October 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt, 11562